The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …”

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…<b>(B)</b> Grand-averaged target-locked neural timescales (mean ± SEM; shaded gray area represents cue-target interval) for three ROIs. …”

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Cells lacking Cbf11 and/or Mga2 display nutrient-responsive decrease in lipid droplet (LD) content. by Anna Marešová (14375187)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(n = 3–4). Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. …”

Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. by Elie Mulhem (22537863)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Anti-SjLLPi1 antibody treatment decreases worm burden in mice 7 days after <i>S. japonicum</i> infection. by Fanyan Chen (3909178)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects: